Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$4.03
-1.1%
$4.37
$3.50
▼
$5.45
$616.99M0.842.94 million shs2.25 million shs
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$17.09
-2.8%
$21.01
$15.85
▼
$30.96
$2.95B0.871.82 million shs1.21 million shs
CareDx, Inc. stock logo
CDNA
CareDx
$69.85
-2.9%
$68.21
$15.56
▼
$90.87
$3.67B2.51976,183 shs534,891 shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$36.99
-1.5%
$39.45
$33.38
▼
$72.66
$3.58B0.111.39 million shs648,326 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-0.58%+1.39%-5.64%-21.57%-4.31%
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-1.35%-3.03%-13.94%-40.37%-23.85%
CareDx, Inc. stock logo
CDNA
CareDx
-3.39%-9.89%+3.93%+47.95%+350.06%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-0.50%-8.37%+3.56%-38.19%-7.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$4.03
-1.1%
$4.37
$3.50
▼
$5.45
$616.99M0.842.94 million shs2.25 million shs
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$17.09
-2.8%
$21.01
$15.85
▼
$30.96
$2.95B0.871.82 million shs1.21 million shs
CareDx, Inc. stock logo
CDNA
CareDx
$69.85
-2.9%
$68.21
$15.56
▼
$90.87
$3.67B2.51976,183 shs534,891 shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$36.99
-1.5%
$39.45
$33.38
▼
$72.66
$3.58B0.111.39 million shs648,326 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-0.58%+1.39%-5.64%-21.57%-4.31%
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-1.35%-3.03%-13.94%-40.37%-23.85%
CareDx, Inc. stock logo
CDNA
CareDx
-3.39%-9.89%+3.93%+47.95%+350.06%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-0.50%-8.37%+3.56%-38.19%-7.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
2.00
HoldN/AN/A
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.72
Moderate Buy$31.1382.12% Upside
CareDx, Inc. stock logo
CDNA
CareDx
2.67
Moderate Buy$70.330.70% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.77
Moderate Buy$71.1592.39% Upside

Current Analyst Ratings Breakdown

Latest ABUS, CDNA, ACAD, and XENE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Lower Price TargetMarket Perform$23.00 ➝ $21.00
11/18/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Lower Price TargetMarket Perform$23.00 ➝ $21.00
11/17/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Lower Price TargetOverweight$82.00 ➝ $80.00
11/13/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Lower Price TargetEqual Weight$28.00 ➝ $24.00
11/11/2026
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
UpgradeHold (C) ➝ Hold (C+)
11/11/2026
CareDx, Inc. stock logo
CDNA
CareDx
Initiated CoverageOverweight$100.00
11/10/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Reiterated RatingHold (C+)
11/6/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Boost Price TargetBuy$36.00 ➝ $38.00
11/5/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Boost Price TargetOutperform$36.00 ➝ $38.00
11/5/2026
CareDx, Inc. stock logo
CDNA
CareDx
UpgradeHold ➝ Strong-Buy
10/30/2026
CareDx, Inc. stock logo
CDNA
CareDx
Boost Price TargetBuy$81.00 ➝ $92.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$14.08M43.82N/AN/A$0.56 per share7.19
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.20B2.46$0.85 per share20.10$8.03 per share2.13
CareDx, Inc. stock logo
CDNA
CareDx
$497.40M7.38$0.01 per share11,428.75$8.90 per share7.85
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$7.50M476.71N/AN/A$11.86 per share3.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$33.50M$1.133.56N/AN/A121.17%129.12%89.26%N/A
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.118.1015.83N/A30.13%8.90%6.86%N/A
CareDx, Inc. stock logo
CDNA
CareDx
-$21.35M$2.3929.2285.18N/A25.86%9.74%7.35%N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$345.91M-$4.70N/AN/AN/AN/A-39.81%-37.98%N/A

Latest ABUS, CDNA, ACAD, and XENE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$0.0232$0.30+$0.3232$0.30$1.00 million$0.30 million
11/9/2026Q3 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.13-$1.11+$0.02-$1.11$0.50 millionN/A
11/4/2026Q3 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.1992$0.31+$0.1108$0.31$332.58 million$342.30 million
10/29/2026Q3 2026
CareDx, Inc. stock logo
CDNA
CareDx
$0.2548$0.70+$0.4452$0.35$121.96 million$139.36 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
N/AN/AN/AN/AN/A
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
CareDx, Inc. stock logo
CDNA
CareDx
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
N/A
1.40
1.40
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.82
3.70
CareDx, Inc. stock logo
CDNA
CareDx
N/A
2.31
2.25
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
21.19
21.19

Institutional Ownership

CompanyInstitutional Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
43.79%
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
CareDx, Inc. stock logo
CDNA
CareDx
N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
19.90%
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.20%
CareDx, Inc. stock logo
CDNA
CareDx
2.40%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
19153.29 million122.79 millionOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
798172.83 million127.55 millionOptionable
CareDx, Inc. stock logo
CDNA
CareDx
76552.54 million51.28 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
36496.67 million93.85 millionOptionable

Recent News About These Companies

How Xenon Pharmaceuticals Inc. (XENE) Affects Rotational Strategy Timing
HC Wainwright Has Negative Outlook for XENE FY2026 Earnings
Xenon (XENE) Q3 2026 Earnings Call Transcript
Xenon Pharmaceuticals Q3 Earnings Call Highlights
Xenon Reports Q3 2026 Financial Results and Provides Business Update
Xenon to Present at Upcoming Investor Conferences

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arbutus Biopharma stock logo

Arbutus Biopharma NASDAQ:ABUS

$4.03 -0.05 (-1.11%)
Closing price 03:59 PM Eastern
Extended Trading
$4.03 0.00 (0.00%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$17.09 -0.50 (-2.82%)
Closing price 03:59 PM Eastern
Extended Trading
$17.07 -0.02 (-0.13%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

CareDx stock logo

CareDx NASDAQ:CDNA

$69.85 -2.07 (-2.88%)
Closing price 03:59 PM Eastern
Extended Trading
$69.96 +0.11 (+0.16%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$36.98 -0.58 (-1.53%)
Closing price 03:59 PM Eastern
Extended Trading
$37.03 +0.05 (+0.14%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.